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Abstract 
Tuberculosis is a bacterial infection caused by Mycobacterium tuberculosis, commonly 
presents as an infection of the alveolar sacs and can be difficult to treat. Granulysin, a lytic 
enzyme employed by CD8 cells during infection, has been shown to degrade M. tuberculosis. 
This project utilizes cloning, transfection, flow cytometry, and qPCR to build lentivirus and 
gamma-retrovirus expressing three isoforms of granulysin. These viruses can be used to infect 
CD8 cells and express human granulysin to better study granulysin’s interaction with 
Mycobacterium tuberculosis. Gaining a more complete understanding of these interactions can 
help identify future targets to help develop a new vaccine against tuberculosis.  
Introduction 
The World Health Organization (WHO) estimated over 10.4 million cases of tuberculosis 
existed worldwide in 2015 [1]. Tuberculosis (TB), a bacterial infection caused by 
Mycobacterium tuberculosis, is most commonly observed as bacteria infecting alveolar sacs of 
the lungs. Symptomatic cases typically result in coughing, chest pain, and trouble breathing [2]. 
While most infections are transmitted through aerosolized droplets, M. tuberculosis can also be 
transmitted through open wounds or ingestion, resulting in infections outside the lung [3]. 
Tuberculosis infection is observed in and documented as two stages, identified as active and 
latent. Latent infections are asymptomatic cases which are not transmissible among people, while 
active infections can be transmitted in many ways, most frequently through airborne particles 
[3].  
Upon infection by M. tuberculosis, macrophages near the site of infection are often the 
first host cells to come into contact with the pathogen. These macrophages phagocytose the 
bacteria in the beginning steps of the humoral immune response [3]. The endocytic vacuole 
containing the phagocytosed pathogen typically fuses with a lysosome, whose lytic enzymes kill 
the pathogen. While some pathogens have developed methods of preventing this fusion from 
occurring in order to prolong survival, it remains unclear the exact mechanism M. tuberculosis 
uses to avoid degradation within the macrophage [3]. The ability of M. tuberculosis to avoid 
destruction by hiding within phagosomes is a major reason why treating such infections can be 
difficult. 
When considering the active cases of tuberculosis documented in 2016, the proportion of 
fatal cases differs dramatically in various countries. For example, 20% of cases in poorer African 
countries result in fatality, while only 5% of cases in more developed countries are fatal [1]. 
Currently, antibiotics are the most widely used method of treatment for tuberculosis infection, 
despite the fact that there are very few known antibiotics which are ultimately successful in 
killing M. tuberculosis. The two most commonly used and effective antibiotics are isoniazid and 
rifampin; these are often prescribed in conjunction with other antibiotics including pyrazinamide, 
doxycycline, and ethambutol in the case of active infections [2]. Though a limited number of 
effective antibiotics against TB have been identified, treatment regimens vary vastly on a case-
by-case basis depending on disease intensity and resistance of each strain. Typically, regimens 
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begin with daily doses of isoniazid, rifampin, pyrazinamide, and ethambutol for eight weeks to 
combat the diseases most aggressive phase and continue with additional doses of isoniazid and 
rifampin for 18 weeks [4]. A significant cause of mortality in developing countries is the 
emergence of antibiotic-resistant M. tuberculosis strains. Attempts to develop a vaccine for 
tuberculosis prevention have not been resoundingly successful to date, though an effective 
vaccine offers a promising alternative to antibiotics and could significantly decrease the burden 
of disease worldwide [1]. 
Research conducted by the Behar lab at the University of Massachusetts Medical School 
in the Department of Microbiology and Physiological Systems focuses primarily on 
understanding the immunological response of the body to a tuberculosis infection. More 
specifically, the lab aims to identify the role of CD8 cytotoxic T-cells during M. tuberculosis 
infection. The goal is to identify particular mechanisms of action of the immune system and steps 
of infection that may be targeted to inform the design and development of vaccines against M. 
tuberculosis. 
During an infection, the human body launches an immune response consisting of many 
distinct components, including two main types of white blood cells: B-cell and T-cell 
lymphocytes. Each of these components serve different purposes in fighting infection. B-cells 
help fight against infection by secreting antibodies specific against antigens. CD8 T-cells act to 
lyse host cells that are infected with virus or bacteria in order to prevent the pathogen from 
replicating and infecting other cells. CD8 T-cells do this by binding to and recognizing antigens 
on the infected cell surface, composed of digested antigen presented on the surface of 
macrophages. This interaction signals the T-cell to release cytotoxic granules into the 
intracellular space, which contain molecules called perforin and granzymes [5]. Perforin works 
by poking holes in the microbial cell wall or membrane of an infected cell so that granzymes can 
enter the cell. Granzymes are serine proteases that induce apoptosis by generally cleaving protein 
peptide bonds within the target cell [6]. An example of one of these granzyme serine proteases is 
an enzyme called granulysin.  
Granulysin is a lytic enzyme encoded by a gene found on Chromosome II. The 
granulysin gene is 3.9 kb long and contains six distinct exons. This gene is transcribed, spliced, 
and translated into three different inactive protein isoforms which are each approximately 15 
kDa, with most difference among isoforms found within the second exon. This 15 kDa precursor 
protein is produced constitutively and has a shorter half-life compared to its 9 kDa counterpart 
although the exact half-lives for each are unknown. Upon stimulation, the precursor is then post-
translationally processed through proteolytic cleavage on both the N- and C-termini into one of 
three active 9 kDa protein isoforms [7]. These three isoforms are referred to in most literature as 
isoforms 519, 520, and 522; their lengths are 390, 420, and 460 base pairs, respectively. Through 
the remainder of this report these isoforms will be referred to as isoforms 1, 2, and 3. Figure 1 
visually summarizes the process involved in expressing and processing the granulysin isoforms.   
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Figure 1: Process of Granulysin Expression; * indicates active form 
 
Differences in the functions of the 15 kDa and 9 kDa isoforms remain unclear, though 
many are hypothesized. Research suggests that while the 15 kDa isoform is expressed and 
secreted constitutively from the CD8 cell, it does not survive long within the cell before it must 
be post-translationally processed [7]. Otherwise, it is quickly degraded. The 15 kDa protein is 
only converted to a 9 kDa protein in the case of a proinflammatory response to help mediate both 
intracellular and extracellular infections, including M. tuberculosis [8]. Little is known about the 
differences between the three 9 kDa isoforms other than that they are formed by alternative 
splicing, and that the variations between isoforms exist mostly within the gene’s second exon. 
Additionally, isoform 2 is widely regarded to be the most prevalent in humans [7].  
Previous research has demonstrated granulysin’s ability to degrade M. tuberculosis when 
directly applied to the bacteria [9]. However, the in vivo interactions between M. tuberculosis 
and active granulysin are not widely understood. As a result, this project aims to better 
understand the role of granulysin during a TB infection. The purpose of this project is to develop 
retroviral vectors expressing each of the three mRNA isoforms of granulysin. Two vectors are 
used for each isoform, resulting in six final constructs. One viral vector is lentivirus using the 
LeGO iG2 plasmid and the second is gamma retrovirus using the pMIGII plasmid. Figure 2 
shows an overview of each viral system used to drive expression of the granulysin isoforms. 
Each mRNA isoform is expressed in two separate viral vector systems because each 
system offers a separate set of advantages for future expression an implementation. Lentiviruses, 
unlike gamma retroviruses, are able to infect non-dividing cells, offering a possible advantage to 
increase expression in T-cells. However, while gamma retroviruses allow for preferential 
insertion sites in target genomes, lentiviruses randomly insert their genetic information into their 
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target. Additionally, lentiviral vectors are shown to have lower transduction efficiency than 
gamma retroviruses [10]. 
 
 
Figure 2: Overview of plasmid system 
  
 Figure 2 depicts key components of both viral vector systems including restriction 
enzyme cut sites, markers, promoters, and envelope/packaging plasmids. The gamma retroviral 
plasmid pMIGII uses a constitutive 5’ LTR promoter which allows for constant expression of 
granulysin isoforms located between EcoRI and BamHI cut sites. The 5’ LTR and the 3’ LTR, 
located between the GFP marker and ampicillin resistance gene, mark the viral coding region of 
the plasmid. The ampicillin resistance gene allows for bacterial colony selection but does not 
influence virus production. pMIGII was transfected with Ecopak packaging plasmid and pVSVG 
envelope plasmid. The broad tropism associated with pVSVG allows for the virus created by the 
system to non-specifically infect many different types of cells.  
 The lentivirus LeGO iG2 uses a constitutive SFFV promoter derived from the spleen 
focus-forming virus which also allows for constitutive expression of granulysin isoforms. The 
SFFV promoter and the 5’ truncated LTR located between the GFP and ampicillin resistance 
genes mark the beginning and end of the gene sequence encoding plasmid production. LeGO iG2 
was transfected with psPAX2 packaging plasmid and pMD2G envelope plasmid which is also 
broadly tropic, similar to pVSVG, and is a widely used lentiviral envelope plasmid.  
The purpose of this project is to develop retroviral vectors expressing each of the three 
mRNA isoforms of granulysin. These three isoforms were cloned into lentiviral and gamma-
retroviral vectors and later transfected into mammalian cells lines where granulysin expression 
was confirmed and quantified. 
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Methods 
 
Cloning of the Granulysin Isoforms 
 
Synthesizing Granulysin and Oligos  
Complete sequences for each of three total granulysin isoforms were synthesized by 
Genscript (Piscataway, NJ) in packaging plasmids with specified cut sites as indicated in Figure 
2. Primers used for PCR reactions were ordered from IDT (Coralville, IA). Primers were 
reconstituted to 100 M with DNase-free water and stored at -20 °C. Table 1 details the name, 
function, and sequence of each primer oligo used for granulysin isolation.  
 
Oligo Name Function Sequence (5’-3’) 
Forward-1,3 Forward primer to amplify 
granulysin isoforms 1 and 3 
from packaging plasmid for 
LeGO and pMIG ligation 
AATAATGGATCCATGGCTACCTGGGCCCTCCTG 
Forward-2 Forward primer to amplify 
granulysin isoform 2 from 
packaging plasmid for LeGO 
and pMIG ligation 
AATAATGGATCCATGGAAGGTCTGGTCTTCTCT 
Reverse-LeGO Reverse primer to amplify 
granulysin isoforms 1, 2 and 3 
from packaging plasmid for 
LeGO ligation 
AATAATCCTGCAGGTCAGAGGGGACCTGT 
Reverse-pMIG Reverse primer to amplify 
granulysin isoforms 1, 2 and 3 
from packaging plasmid for 
pMIG ligation 
AATAATCTCGAGTCAGAGGGGACCTGTAGAAGG 
Table 1: Name, function, and sequence of each primer oligo used for granulysin isolation 
 
Granulysin Amplification and Isolation by  PCR 
Polymerase Chain Reaction (PCR) using the ThermoFisher Phusion Hot Start Flex 
Polymerase kit and 100 g of template DNA was used to amplify and isolate all three granulysin 
isoforms from the packaging plasmids in which they resided. Primers that were designed and 
ordered to match each isoform also contained restriction enzyme sites which would be later used 
for ligation purposes. The PCR protocol used was the following: initial denature at 98 °C for 30 
sec followed by 98 °C for 10 sec, 59 °C for 30 sec, and 72 °C for 30 sec repeated 33 times, with 
a final extension of 72 °C for 10 minutes.  
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Gel Electrophoresis  
Subsequent to PCR to isolate and amplify the three granulysin isoform inserts, a 1.2% 
agarose gel was run in order to determine if the three insert sizes matched the expected size for 
each isoform. Table 2 details the expected sizes for each isoform.  
 
Isoform # Expected Size (base pairs) 
1 390 
2 420 
3 522 
Table 2: Expected sizes for each granulysin isoform 
 
Restriction Digest  
Double restriction digests were run on PCR reaction products. LeGO was cut by Sbf1 and 
BamHI restriction enzymes and pMIG was cut by EcoRI and XhoI restriction enzymes, each in 
CutSmart reaction buffer. The protocol for the restriction digest was followed exactly from the 
NEB restriction digest protocol. Reactions were incubated for one hour at 37 °C. 
 
Ligation 
Each of the three granulysin isoforms were ligated with both LeGO lentivirus or pMIG 
gamma retrovirus backbones resulting in six unique ligation reactions. Reactions were performed 
by exactly following the NEB T4 ligation protocol. The final volume for each reaction was 20 
L and reactions were placed in a thermocycler and run at 16 °C overnight. The ligation reaction 
was heat inactivated at 65 °C for 15 minutes.  
 
Transformation 
Eight samples (six experimental and two negative controls) were then transformed using 
the NEB High Efficiency Transformation Protocol along with pUC19 positive control. 10 L of 
each sample and 2 L of the positive control were used for the transformations. Transformation 
plates were incubated on LB + ampicillin plates at 37 °C overnight.  
 
Colony PCR 
Eight colonies were picked from each experimental plate and inoculated in LB + 
ampicillin medium to grow liquid cultures overnight for DNA isolation. Each colony was also 
used to provide template plasmid for PCR amplification. ThermoFisher Taq polymerase and Hot 
Start Flex Master Mix kit were used along with 10.0 M forward and reverse primers used for 
granulysin isolation. The PCR protocol used was the following: initial denature at 98 °C for 30 
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sec followed by 94 °C for 10 sec, 59 °C for 30 sec, and 72 °C for 15 sec repeated 33 times with a 
final extension of 72 °C for 10 minutes. 
  
DNA Isolation 
DNA was isolated using the QIAprep Spin Miniprep Kit from colonies harboring vectors 
containing granulysin as determined from colony PCR and diagnostic gel electrophoresis results. 
The protocol was followed exactly from the QIAprep Kit instructions. DNA concentration and 
purity were determined using Nanodrop.  
 
Sequence Confirmation 
 Purified plasmid DNA from selected colonies were sent to Etonbio along with primers 
used for granulysin isolation and following their instructions for sequencing. Sequence results 
were aligned and cross-examined in Benchling with known granulysin isoform sequences. 
Plasmids with sequences which aligned with expected sequences were used moving forward for 
transfections into mammalian cell lines.  
 
Transfecting Cloned Plasmid into Mammalian Cell Lines  
 
Cell Culture Techniques and Protocols  
Cell culture medium used was 10% Fetal Bovine Serum (FBS) complete RPMI (cRPMI) 
sterile filtered through a 0.22-micron filter. The mixture for cRPMI was as follows:  
 
RPMI Medium – 425 mL 
FBS – 50 mL 
HEPES Buffer – 5 mL 
Non-Essential Amino Acids (NEAA) – 5 mL 
Penicillin/Streptomycin Antibiotic Mixture (Penstrep) – 5 mL 
Sodium Pyruvate – 5 mL 
L-Glutamine – 5 mL 
 
All mammalian cell culture procedures and methods were performed in a sterile hood and 
all cell lines were grown in a 37 °C incubator with 5% CO2 and humidified air.  
 
Transfection Protocols  
Viral plasmids for granulysin isoforms 1, 2 and 3 were used to transiently transfect 293T 
embryonic kidney cells. Supernatant, containing virus, from 293T cells transfected by isoforms 
expressed by gamma-retroviral plasmids was then used to transfect stable cell lines of GP+E86 
fibroblasts. Supernatant from 293T cells transfected by isoforms expressed by lentiviral plasmids 
was saved for future titering purposes. Both transient and stable transfections were performed by 
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exactly following the protocol provided in Generation of T-cell receptor retrogenic mice steps 
19-27 [11]. 
  
Flow Cytometry, Cell Sorting and Titering 
 
MACSQuant Flow Cytometry 
 After transient (293T) and stable (GP+E86) transfections, cell lines expressing granulysin 
isoforms and non-transfected controls were grown to confluence. The cells were harvested by 
trypsinization, washed in RPMI, and counted in cRPMI with FBS. 100 L of solution from each 
sample were taken and cells were resuspended in 100 L of MACS buffer (2% calf serum 98% 
PBS) while the remaining cells were washed again using RPMI. Cells resuspended in MACS 
buffer were screened using MACSQuant Analyzer flow cytometry to identify GFP+ fluorescence 
of each population.  
 Cell populations were gated using forward scatter (FSC) vs side scatter (SSC) to identify 
the cell population within solution that most closely matched the expected size of living cells. 
This population was then gated using FSC vs FSC in order to identify single cells in the 
population because cells that clump together are more likely to be dead or abnormal. This final 
cell population was analyzed using SSC vs FITC (GFP) to visualize how many of the living, 
single cells in each sample were positive for GFP fluorescence.  
 
GFP+ Cell Sorting 
After successful transfections into GP+E86 cells were confirmed by flow cytometry, the 
remaining cells from each sample were resuspended in 1% FBS in DPBS (with no calcium, 
magnesium, or phenol red) running medium at a concentration of 1 million cells per mL. 
Additional collection medium of 20% FBS in RPMI and cRPMI with gentamycin and fungizone 
was prepared. The running medium cell suspension and collection medium were taken to the 
University of Massachusetts Medical School cell sorting service to sort and collect the top 50% 
of GFP+ cells. These cells were cultured and grown as previously indicated to confluence.  
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Titering 
 In a 6-well plate, 2 million stable transfected GP+E86 cells expressing isoform 2 or 3 
were plated in 2 mL of cRPMI and incubated at 37 °C for 24 hours to produce concentrated 
virus. Virus used to titer isoform 1 was retrieved from medium removed and frozen during 
harvests one and six of lentiviral transfection. Experimental plate set-up for all isoforms are 
depicted in Figure 3. Dilutions used to determine viral titer for isoforms 2 and 3 were made by 
exactly following the titering protocol in Generation of T-cell receptor retrogenic mice steps 31-
35 [11]. The same titering protocol used for isoforms 2 and 3 was also used for isoform 1 except 
isoform 1 virus was not diluted.   
 Transfected titer plates were left to incubate for 72 hours and analyzed using flow 
cytometry for GFP+ cells. Final titer was determined by identifying the dilution for each isoform 
that produced a percentage of GFP+ cells closest to 50% and using the formula: 
percent positive x 0.01 x dilution factor x 104 to determine titer for each isoform.  
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qPCR mRNA Quantification  
 GP+E86 cells were lysed and RNA was isolated using the TRIzol Reagent RNA isolation 
protocol (Invitrogen). Isolated RNA was then transcribed into cDNA using by following the 
Invitrogen Superscript III kit protocol. Random hexamers were used as primers to transcribe 
cDNA non-specifically.   
 qPCR analysis was used to quantify the expression of granulysin in GP+E86 in 
conjunction with a -Actin control and a non-transfected GP+E86 control. The -Actin control 
was used to normalize the production of granulysin within each sample. The qPCR reactions 
were set up using the following reaction: 
 
10 L – ThermoFisher Fast SYBR green master mix 
1 L - Paired 20 M forward and reverse primer mixture  
8 L - RNAse free water  
1 L - 1:10 dilution cDNA 
 
Granulysin primers used for qPCR analysis were non-specific to various granulysin isoforms. 
Forward and reverse primer sequences used in the reaction are shown in Table 3.  
 
Oligo name Function Sequence (5’-3’) 
qPCR- Forward Forward primer to amplify all 
isoforms of granulysin for qPCR 
analysis 
GTGAAGAGACCCACCCGAATAG 
qPCR- Reverse Reverse primer to amplify all 
isoforms of granulysin for qPCR 
analysis 
TAGGACGGGGAGGTCACG 
Table 3: Name, function, and sequence of granulysin primer oligos used for qPCR analysis 
 
Finally, the qPCR reaction was set-up in a 96-well plate as depicted in Figure 4.  
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The qPCR reaction was run under the following thermocycling conditions:  
 Activation - 95° C for 20 sec 
 Denature - 95° C for 3 sec 
 Anneal/Extend - 60° C for 30 sec 
 Repeat denature and anneal/extend cycles 40 x 
 
Average Ct values were determined for each triplicate reaction and Ct values were determined 
by subtracting the average -Actin Ct values from the average granulysin Ct values for each 
isoform. Relative expression was determined compared to -Actin and non-transfected 
granulysin controls by using the equation: 2-Ct.  
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Results 
 
DNA Cloning 
 
 
 
 
 
 
  
 
 
 
 
 
 
pMIG 1 
Colonies 1-8 
LeGO 1 
Colonies 1-8 
LeGO 2 
Colonies 1-8 
Lego 3 
Colonies 1-8 
NTC NTC NTC NTC 
pMIG 2 
Colonies 1-8 
pMIG 3 
Colonies 1-8 
NTC NTC 
Figure 6: Results from colony PCR 
500 
bp  
500 
bp  
Figure 5: Granulysin isoforms amplified from 
packaging plasmids 
 
500 
bp  
Gel electrophoresis results from granulysin 
isolation and amplification shown in Figure 5 
indicate that all three isoforms were amplified to 
their expected sizes. The no template control 
(NTC) was used as a negative control in order to 
ensure there was no contamination in the reactions. 
These sequences and backbone plasmids (LeGO 
and pMIGII) were digested using restriction 
enzymes to create compatible overhangs between 
backbones and inserts. Granulysin and backbone 
plasmids were then ligated and transformed into 
DH5α E. coli cells. Eight colonies were picked 
from each plate and were tested using colony PCR 
to determine if they harbored the vector containing 
the expected granulysin isoforms. Figure 6 shows  
results of colony PCR. DNA from granulysin-positive colonies was sent to be sequenced to confirm 
proper granulysin insertion. Sequencing results were analyzed in Benchling (Figure 7) and confirmed 
granulysin incorporation in the following plasmids: isoform 1 in LeGO backbone, isoform 2 in pMIG 
II backbone, and isoform 3 in pMIG II backbone. 
M         1         2       3      NTC 
    Isoform 
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Transfections 
 293T cells were transiently transfected using each of the confirmed retroviral plasmids, 
three transfections in total. Flow cytometry was used to determine the transfection efficiency in 
these cells by quantifying GFP fluorescence in the cell populations. Figure 8 panel A and B show 
the gating process used to confirm fluorescence in 293T cells. Panel C depicts non-transfected 
wildtype control and panel D depicts the transfected isoform 2 cell line. The cell line transfected 
with vector shows much higher fluorescence than non-transfected wildtype. Flow cytometry on 
293T cells transfected with isoforms 1 and 3 yielded the same results.  
 
 
 
 
 
Figure 8: Forward scatter vs side scatter (A) and forward scatter vs forward scatter (B) of 293T cells 
used to gate sample populations. FITC fluorescence vs side scatter used to determine transfection 
efficiency in wildtype 293T population (C) and 293T population transfected with granulysin isoform 2 
(D) shows higher GFP+ fluorescence in transfected cell lines.  
 
Figure 7: Example of sequencing results showing sample match to expected granulysin sequence 
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After transient transfections into 293T cells were confirmed by flow cytometry, isoforms 
2 and 3 were transfected into GP+E86 stable cell lines. Transfections into GP+E86 fibroblasts 
were also confirmed by flow cytometry as shown in Figure 9. Increased fluorescence of isoforms 
2 and 3 compared to the wildtype confirmed successful transfection into fibroblasts.  
 
 
 
 
 
 After transfection was confirmed in GP+E86 cell lines and cells were sorted to isolate the 
top 50% most GFP+, qPCR was used to quantify granulysin mRNA expression in isolated. 
Figure 10 shows granulysin expression normalized to an external B-actin control and normalized 
to a non-transfected control. Wildtype, isoform 2 and isoform 3 samples had equivalent B-actin 
expression with average Ct values of 23.8, 24.6, and 23.7 respectively. Relative granulysin 
expression compared to B-actin was calculated and displayed in Figure 10. Low granulysin 
expression in wildtype control and high granulysin expression in transfected samples confirms 
the results obtained by flow cytometry, namely that cells transfected with granulysin isoforms 
express granulysin mRNA.  
 
Figure 9: Normalized FITC fluorescence across wildtype (orange) and transfected (blue & red) GP+E86 
cell lines also shown increased fluorescence in transfected cell lines. 
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Finally, titering experiments were performed to determine the viral load produced by the 
transfected cell lines. Titer was derived by using flow cytometry to determine the number of 
GFP+ cells per well. Analysis showed isoforms 2 and 3 produced significantly higher viral loads 
than Isoform 1. Titer values are shown in Table 4.  
 
 
ISOFORM # DILUTION %GFP+ TITER 
ISOFORM 1 No dilution 34 0.03x105 
ISOFORM 2 1:33 35 1.16x105 
ISOFORM 3 1:10 49 0.49x105 
 
 
 
 
Figure 10: qPCR analysis of cDNA from lysed GP+E86 cells show six-fold more granulysin 
production in transfected cells than wildtype relative to consistent β-actin control. 
Table 4: Titer analysis of granulysin isoforms 
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Discussion 
 
The objectives of this project were to design and build retroviral plasmids containing 
three granulysin isoforms, transfect mammalian cells lines with granulysin-expressing 
retroviruses, and quantify expression in transfected cell lines. Overall, project objectives were 
met. 
  Attempts to clone granulysin isoforms into retroviral backbones were successful, 
resulting in sequence-confirmed plasmids containing each isoform. The key limiting factor 
throughout the cloning process was time. Lack of available time led to progressing with only one 
or two unique isoforms cloned into either lentiviral or gamma-retroviral backbones. Moving 
forward, successfully cloning the remaining retroviral plasmids would allow for a more wholistic 
analysis of the lenti and gamma-retroviral systems, as well as all three granulysin isoforms in 
comparison to one another. 
 Transient transfections of isoforms 1, 2 and 3 into 293T cells and stable transfections of 
isoforms 2 and 3 into GP+E86 cells where shown to be successful using flow cytometry. 
Fluorescence along with qPCR data confirmed successful transfections (via GFP) and expression 
of granulysin mRNA (via qPCR) in GP+E86 cells transfected by isoform 2 and 3 gamma-
retroviruses.  
Titering data reveals significantly lower viral yield from isoform 1 compared to isoforms 
2 and 3. This could be the result of using medium from the first harvest of the lentiviral 
transfections for the titering protocol. Repeating titering experiments using medium from later 
harvests could result in higher titers as there was likely more viral production during harvests 2-5 
of lentiviral transfection. Alternatively, lower titers could be the result of the lentiviral plasmid 
itself. Literature regarding lentiviral gene vectors suggests that lentiviruses tend to produce lower 
titers than gamma-retroviruses [10]. Additionally, re-sorting GP+E86 stable cell lines to isolate 
top 10% GFP+ cells could also help increase viral titers in isoforms 2 and 3 if necessary for 
future transfections into T-cells. However, because sorting the top 50% of GFP+ cells yielded 
approximately 700,000 cells per isoform, sorting the top 10% of GFP+ cells would likely yield 
fewer cells.  
 The intent of the Behar lab is to continue moving forward with isoforms 2 and 3 
confirmed in pMIG gamma-retroviral plasmids. These isoforms will be transfected into T-cells, 
and granulysin protein production and activity will be confirmed. SDS PAGE gels with 
immunoblots will confirm protein-level granulysin expression, and ELISA assays will confirm 
enzyme activity. Isoform non-specific anti-granulysin antibodies are available for purchase 
through Invitrogen, Biolegand, and several other companies. The eventual goal of the Behar lab 
is to use retroviral plasmids containing human granulysin to create a retrogenic mouse model that 
can be used to study interactions between granulysin and Mycobacterium tuberculosis over the 
course of infection. The successful completion of this projects work has been a necessary and 
important step toward realizing the goal of this research.  
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